274 filings
8-K
XFOR
X4 Pharmaceuticals Inc
22 May 24
Regulation FD Disclosure
8:09am
8-K
XFOR
X4 Pharmaceuticals Inc
9 May 24
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105
6:58am
10-Q
2024 Q1
XFOR
X4 Pharmaceuticals Inc
Quarterly report
7 May 24
4:23pm
8-K
XFOR
X4 Pharmaceuticals Inc
7 May 24
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
6:28am
ARS
2023 FY
XFOR
X4 Pharmaceuticals Inc
29 Apr 24
Annual report to shareholders
4:58pm
DEFA14A
h4kenae0
29 Apr 24
Additional proxy soliciting materials
4:55pm
8-K
alhim3p a8kuv79kn
29 Apr 24
Regulation FD Disclosure
8:30am
8-K
03rfuq
29 Apr 24
X4 Pharmaceuticals Announces FDA Approval of XOLREMDIâ„¢ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
6:30am
8-K
uzb0jz0aqhzv q22ccuf
5 Apr 24
Other Events
4:30pm
8-K
4xde4xvml 032j
1 Apr 24
Regulation FD Disclosure
9:20am
8-K
th2amb
21 Mar 24
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial
7:43am
S-8
oamc1
25 Jan 24
Registration of securities for employees
4:23pm
8-K
h2w369i 8vr011p5z
8 Jan 24
Regulation FD Disclosure
4:08pm
8-K
8x78n9ffc0 gpg9
27 Nov 23
Regulation FD Disclosure
5:20pm
8-K
gaiqleqakoxmzlun589
14 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:10pm
8-K
nkzj7s5wqlngpie
9 Nov 23
X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates
8:07am
8-K
fl9q8egvt9fejg 0vc
31 Oct 23
X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome
4:25pm